The cell therapy product ImmunoArt consists of in vitro expanded allogeneic MSCs from bone marrow,  manufactured under the highest GMP standards. The final cell suspension is administered systemically as a bolus in a multiple dose regimen.

Due to its immunomodulatory capacity, the ImmunoART cell therapy product is suitable for the treatment of various diseases where the immune system is deregulated.

To date, 14 refractory acute GvHD patients have been treated without serious adverse events and complete remission has been achieved in some of them. It is important to start treatment as early as possible during the development of GvHD.


To date, 7 severe COVID-19 ARDS patients


A young patient with sacroiliitis reported pain relief and a decrease in inflammatory laboratory markers after multiple dosing.


Educell's scientific publications